NEW YORK – Metastatic colon cancer patients are being undertested for guidelines-backed genomic markers, which means that many of them are losing out on the chance to receive precision therapies, a recently published study suggests.
Colon Cancer Biomarker Undertesting Rates in Real-World Data Points to Precision Oncology Barriers
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.